Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance

• Main Authors: YANG Liu, ZHU Xiling, LI Gong
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2016-08-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=7631

In recent years, the immunotherapy based on the blocking of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has achieved encouraging progress in the treatment of malignant tumors such as melanoma and lung cancer. More and more studies have focused on its role in hepatocellular carcinoma (HCC). This article introduces the mechanism of action of PD-1/PD-L1, expression of PD-L1 in HCC tissues, and its basic and clinical research in the treatment of HCC, and points out that PD-L1 plays an important role in tumor immune escape and is expected to become an independent index for evaluating the prognosis of HCC. The discovery of PD-1/PD-L1 pathway provides a new target for immunotherapy for HCC.